Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of DirectorsGlobeNewsWire • 10/23/25
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 10/23/25
Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With ChugaiSeeking Alpha • 10/20/25
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai PharmaReuters • 10/17/25
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 10/17/25
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million FinancingGlobeNewsWire • 10/17/25
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate UpdateGlobeNewsWire • 08/07/25
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct OfferingGlobeNewsWire • 07/15/25
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous DeliveryGlobeNewsWire • 07/14/25
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateGlobeNewsWire • 05/13/25
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate UpdateGlobeNewsWire • 03/31/25
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102GlobeNewsWire • 03/26/25
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 03/25/25
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing WarrantsGlobeNewsWire • 10/15/24
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate UpdateGlobeNewsWire • 08/06/24
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct OfferingGlobeNewsWire • 07/22/24
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity TreatmentGlobeNewsWire • 06/24/24